NAS:FATE (USA) Also Trade In: Germany
Fate Therapeutics Inc $ 47.46 0.56 (1.19%)
Warning! GuruFocus has detected 3 Severe warning signs with FATE. Click here to check it out.
Avg Vol (1m):
Market Cap $:
Enterprise Value $:
Current and historical daily P/E ratio for FATE (Fate Therapeutics Inc) from 2013 to Oct 27 2020. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The P/E ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the P/E ratio is positive. Also for stocks with the same P/E ratio, the one with faster growth business is more attractive. Fate Therapeutics stock (FATE) PE ratio as of Oct 27 2020 is 0. More Details
Fate Therapeutics PE Ratio (TTM) Historical Data
View and export this data going back to 2013. Start your Free Trial
Fate Therapeutics PE Ratio (TTM) Comparison
|Company||Market Cap(Mil)||PE Ratio (TTM)|
Compare NAS:ARNA NAS:AXSM NAS:QURE NAS:VIE NAS:NVAX NAS:DNLI NAS:AMRN NAS:KOD NAS:INSM NAS:FOLD OCSE:NOVO B ASX:CSL NAS:VRTX NAS:REGN XKRX:207940 NAS:SGEN NAS:MRNA NAS:ALXN XKRX:068270 NAS:INCY
Address 3535 General Atomics Court, Suite 200, San Diego, CA, USA, 92121
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and immune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.